Statements achieving consensus (≥75% of respondents choosing strongly agree)
| Statement | Responses: strongly agree |
| DI-ILD should be considered when patients present with respiratory symptoms while receiving treatment with a drug known to be associated with DI-ILD | 30 (91%) |
| DI-ILD should be suspected if there are radiological and physiological abnormalities emerging in a patient taking a drug known to cause DI-ILD | 28 (85%) |
| DI-ILD should be strongly suspected if there is a temporal relationship between commencing a drug known to cause DI-ILD and symptom onset | 28 (85%) |
| When a patient presents with new respiratory symptoms while using a medication known to cause DI-ILD, and should initial investigations and treatment not resolve the clinical scenario, investigations should include pulmonary function tests (spirometry and transfer factor) | 28 (85%) |
| When a patient presents with new respiratory symptoms while using a medication known to cause DI-ILD, and should initial investigations and treatment not resolve the clinical scenario, investigations should include chest radiography and HRCT scan | 28 (85%) |
DI-ILD: drug-induced interstitial lung disease; HRCT: high-resolution computed tomography.